Danone Invests Further in Gut Health and Next-Generation Biotic ScienceWILMINGTON, Del., June 25, 2025 (GLOBE NEWSWIRE) -- The Akkermansia Company (TAC) today announces that it has been acquired ...

The company has broad patents protecting the use of the Akkermansia species, including the use of the pasteurized version of the strain, MucT, which is its most bio-efficacious form.

After becoming available in its Belgian home market in 2021, the company is now expanding sales of Akkermansia muciniphila MucT ® into key markets in Europe, North America and Asia.

VIVES Partners created The Akkermansia Company in 2016, from its outset bringing together a solid consortium of shareholders, including an €18M funding in 2018 with two key lead investors ...

Recent advances in cardiovascular research increasingly recognize the gut microbiome as a pivotal factor influencing cardiovascular disease (CVD) pathogenesis and treatment outcomes. The intricate ...

TAC develops health products based on the unique properties of the Akkermansia muciniphila commensal bacterial species. The company has broad patents protecting the use of the Akkermansia species, ...

TAC’s founding scientists first discovered the biotic strain Akkermansia muciniphila MucT in 2004 and have since developed it using state-of-the-art technology.